These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 65135)

  • 41. [Replacement therapy using macromolecules: general hemodynamic effects].
    Conseiller C; Viars P
    Anesth Analg (Paris); 1976; 3(4):633-46. PubMed ID: 1015651
    [No Abstract]   [Full Text] [Related]  

  • 42. [Immunological findings in infusions of colloidal solutions].
    Richter W; Hedin H; Ring J
    Med Welt; 1977 Oct; 28(42):1717-9. PubMed ID: 73122
    [No Abstract]   [Full Text] [Related]  

  • 43. [Side effects of colloidal plasma substitutes].
    Bergmann H
    Beitr Infusionther Klin Ernahr; 1981; 8():33-42. PubMed ID: 6172109
    [No Abstract]   [Full Text] [Related]  

  • 44. [Anaphylactoid complications related to the use of 40,000- molecular weight dextran].
    Laxenaire MC; Jacob F; Noel P
    Ann Anesthesiol Fr; 1976; 17(2):101-4. PubMed ID: 62526
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of safer plasma substitutes.
    Gollub S; Vanichanan C; Schaefer C; Schechter DC
    Surg Gynecol Obstet; 1969 Jun; 128(6):1235-43. PubMed ID: 5781849
    [No Abstract]   [Full Text] [Related]  

  • 46. [Cellular mechanisms of anaphylaxis].
    Gushchin IS
    Patol Fiziol Eksp Ter; 1973; 17(5):3-15. PubMed ID: 4133210
    [No Abstract]   [Full Text] [Related]  

  • 47. Pretreatment with dextran 1 makes dextran 40 therapy safer.
    Ljungström KG
    J Vasc Surg; 2006 May; 43(5):1070-2. PubMed ID: 16678710
    [No Abstract]   [Full Text] [Related]  

  • 48. [Extreme hemodilution with molecular weight gelatin solution].
    Klövekorn WP; Sunder-Plassmann L; Messmer K
    Z Gesamte Exp Med Einschl Exp Chir; 1971; 156(4):243-58. PubMed ID: 4111982
    [No Abstract]   [Full Text] [Related]  

  • 49. [Infusion therapy with dextrans. Clinical results of a multicentric study].
    Gregori M
    Beitr Infusionther Klin Ernahr; 1981; 8():98-9. PubMed ID: 6172115
    [No Abstract]   [Full Text] [Related]  

  • 50. Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules.
    Mishler JM; Hester JP; Huestis DW; Rock GA; Strauss RG
    J Clin Apher; 1983; 1(3):130-43. PubMed ID: 6085930
    [No Abstract]   [Full Text] [Related]  

  • 51. [Death caused by infusion of low-molecular dextran].
    Plamieniak L; Kowal-Gierczak B; Kotschy M; Kurzawska M; Kozlowska B
    Wiad Lek; 1974 May; 27(10):901-5. PubMed ID: 4839858
    [No Abstract]   [Full Text] [Related]  

  • 52. [Mechanisms of anaphylactoid reactions to drugs used in anesthesiology].
    Moneret-Vautrin DA
    Ann Anesthesiol Fr; 1977; 18(7-8):679-84. PubMed ID: 74222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of histamine release in anaphylactic and anaphylactoid reactions.
    Kazimierczak W; Diamant B
    Prog Allergy; 1978; 24():295-365. PubMed ID: 78497
    [No Abstract]   [Full Text] [Related]  

  • 54. New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood.
    Kopecek J; Sprincl L; Lïm D
    J Biomed Mater Res; 1973 Mar; 7(2):179-91. PubMed ID: 4267380
    [No Abstract]   [Full Text] [Related]  

  • 55. [Main features of the mechanism of action of plasma substitutes and typical errors in their use].
    Koziner VB
    Gematol Transfuziol; 1983 Sep; 28(9):5-11. PubMed ID: 6195044
    [No Abstract]   [Full Text] [Related]  

  • 56. Renal toxicity of low molecular weight dextran: a review of the literature.
    Figueroa JE; Burgos-Calderon R
    J La State Med Soc; 1974 Dec; 126(12):425-7. PubMed ID: 4436605
    [No Abstract]   [Full Text] [Related]  

  • 57. [Intolerance reactions after plasma substitutes].
    Schmidt H; Pfluger H
    Anesth Analg (Paris); 1971; 28(5):871-8. PubMed ID: 5158890
    [No Abstract]   [Full Text] [Related]  

  • 58. [Disseminated intravascular coagulation during Rheomacrodex therapy].
    Hajnal F; Kiss Z
    Orv Hetil; 1983 Mar; 124(11):641-2. PubMed ID: 6189045
    [No Abstract]   [Full Text] [Related]  

  • 59. [Side-effects in patients treated with dextran].
    Kowal-Gierczak B; Janukowicz-Lorenz H
    Wiad Lek; 1974 Feb; 27(4):341-5. PubMed ID: 4130922
    [No Abstract]   [Full Text] [Related]  

  • 60. Probable grade IV dextran-induced anaphylactic reaction despite hapten inhibition.
    Bircher AJ; Hédin H; Berglund A
    J Allergy Clin Immunol; 1995 Feb; 95(2):633-4. PubMed ID: 7531733
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.